Leveraging our strengths in high-throughput screening technology we provide the fastest methods for directed studies of in vivo gene function which results in earlier identification of therapeutic targets. In combination with the rapid development time of small model organisms (4 days) our systems enable rapid iterations to shorten drug development times. We generate humanized transgenic models for mechanism of drug action studies preventing costly drug failures in later stages.

2013 Boston Silver Winner
Sub industry